Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1225 AUD | +2.08% | +2.08% | +6.52% |
Mar. 26 | Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise | MT |
Mar. 20 | Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% | MT |
Sales 2022 | 296K 195K | Sales 2023 | 1.45M 957K | Capitalization | 42.5M 27.94M |
---|---|---|---|---|---|
Net income 2022 | -8M -5.26M | Net income 2023 | -10M -6.58M | EV / Sales 2022 | 32 x |
Net cash position 2022 | 5.93M 3.9M | Net cash position 2023 | 5.18M 3.4M | EV / Sales 2023 | 25.7 x |
P/E ratio 2022 |
-1.47
x | P/E ratio 2023 |
-3.49
x | Employees | 27 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.45% |
1 day | +2.08% | ||
1 week | +2.08% | ||
Current month | -18.33% | ||
1 month | +6.52% | ||
3 months | -18.33% | ||
6 months | +34.62% | ||
Current year | +6.52% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Baker
CEO | Chief Executive Officer | - | 20-01-01 |
Tim Luscombe
DFI | Director of Finance/CFO | - | Nov. 30 |
Michelle Long
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 62 | 22-06-30 |
Elizabeth Stoner
BRD | Director/Board Member | 73 | 21-11-09 |
Thomas Duthy
CHM | Chairman | - | 23-03-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 0.1225 | +2.08% | 523 695 |
24-05-02 | 0.12 | 0.00% | 664,667 |
24-05-01 | 0.12 | -4.00% | 569,944 |
24-04-30 | 0.125 | +4.17% | 941,962 |
24-04-29 | 0.12 | 0.00% | 396,116 |
Delayed Quote Australian S.E., May 02, 2024 at 11:29 pm EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.52% | 81.85M | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- ALA Stock